Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1273 Vaccine in Patients With Cancer
NCT04847050Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2021
- Primary completion
- May 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of elasomeran in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Adverse Events at 19.5 months, Reactogenicity at 15 minutes and 1 more. Started Apr 2021; status: completed.
02
Drugs
elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04847050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04847050.